Q2 2026 Photocure ASA Earnings Call Transcript

Jul 29, 2026 / 12:00 PM GMT

Release Date Price: $6.01

Transcript

Key Points

Positve

PhotoCure ASA (PHCUF) reported an 11% product revenue growth in Q2 2026, with North America achieving a 12% increase.
The company has no debt on its balance sheet, providing financial stability.
PhotoCure ASA (PHCUF) completed the acquisition of Vesica Health, enhancing its leadership in bladder cancer diagnostics.
The FDA reaffirmed plans to reclassify BLC equipment, potentially expanding the U.S. market.
The company has a strong cash position with $162.4 million NOC at the end of Q2 2026.

Negative

Reported EBITDA was negative $2 million NOC, indicating financial challenges.
Operating expenses increased by 21% compared to the previous year, impacting profitability.
The company is in arbitration with Osiris, which could affect future collaborations.
There are specific account-level challenges in the Nordic region, particularly in Sweden.
PhotoCure ASA (PHCUF) faces significant headwinds from currency fluctuations, impacting revenue growth.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

PHO.OL - Photocure ASA
Q2 2026 Photocure ASA Earnings Call
Jul 29, 2026 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
All right. Well, good afternoon. Good morning. I'm Dan Schneider, President and CEO of Photocure. Welcome to today's presentation of second quarter 2026 results. With me today is Priyam Shah, our Vice President of Investor Relations and **** Peters, our Vice President of Finance and IT.

Just a reminder that the usual disclaimers are in effect for today's presentation.

So the slide you've seen before, this is Photocure's corporate strategy. It's centered on three priorities that guide execution and capital allocation. First is strengthening the core, drive disciplined growth in Hexfix and SysU franchise by expanding blue light cystoscopy tower installations, upgrades, and the US mobile BLC adoption while increasing penetration

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.